Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 1-2

  Zalcman, G ^a,b,c   Bergot, E ^a,b,c   Lechapt, E ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c French Intergroup for Thoracic Cancer research ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED; THYMIDYLATE SYNTHASE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; LUNG RESECTION; PATIENT CARE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLATINUM; PLEURAL NEOPLASMS;

EID: 79952194560     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.12.021     Document Type: Editorial

References (14)

1. Ugolini D., Neri M., Casilli C., Ceppi M., Canessa P., Ivaldi G., et al. A bibliometric analysis of scientific production in mesothelioma research. Lung Cancer 2010, 70:129-135.
2. Trousse D.S., Avaro J.P., D'Journo X.B., Doddoli C., Astoul P., Giudicelli R., et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg 2009, 36:759-763.
3. Rusch V., Giroux D., Edwards J., Waller D., Kennedy C., Ruffini E., et al. Initial analyses of the IASLC International Database for Malignant Pleural Mesothelioma (MPM). J Thorac Oncol 2009, 4:s322. (Abstr. B1.7).
4. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135. 620-626, 626, e621-623.
5. Krug L.M., Pass H.I., Rusch V.W., Kindler H.L., Sugarbaker D.J., Rosenzweig K.E., et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:3007-3013.
6. Van Schil P., Baas P., Gaafar R., Maat A., van de Pol M., Hasan B., et al. Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol 2009, 27. (Abstr. 7509).
7. Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M., Lowry E., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
8. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
9. Katirtzoglou N., Gkiozos I., Makrilia N., Tsaroucha E., Rapti A., Stratakos G., et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010, 11:30-35.
10. Dowell J.E., Lan C., Gerber D., Hughes R., Yan J., Xie Y., et al. Pemetrexed, cisplatin, and bevacizumab in patients with advanced malignant mesothelioma: a multi-center phase II trial. J Thorac Oncol 2009, 4:s319. (Abstr. B1.2).
11. Santoro A., O'Brien M.E., Stahel R.A., Nackaerts K., Baas P., Karthaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008, 3:756-763.
12. Righi L., Papotti M.G., Ceppi P., Bille A., Bacillo E., Molinaro L., et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010, 28:1534-1539.
13. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16:923-927.
14. Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.